Kristen Sheppard joined Centessa in June 2022 as Senior Vice President, Investor Relations and Corporate Communications. Kristen has more than 25 years of experience in building and leading successful investor relations, corporate communications and public affairs functions across the biotechnology, medical device, and technology sectors.
Kristen joined Centessa from Dicerna Pharmaceuticals, Inc. where she served as Senior Vice President, Investor Relations and Corporate Communications through its acquisition by Novo Nordisk. Prior to Dicerna, Kristen was Senior Vice President, Investor Relations and Corporate Communications at Akebia Therapeutics, Inc. Kristen was also Vice President, Investor Relations and Counsel at NxStage Medical, Inc. from 2008 through its acquisition by Fresenius Medical Care in 2019, serving most recently as the company’s Associate General Counsel. Prior to NxStage, Kristen held senior leadership roles in investor relations for publicly traded and pre-IPO companies within the technology sector, and also served as senior government affairs and public policy counsel to various healthcare entities.
Kristen holds a Juris Doctor degree from Suffolk University Law School and a Bachelor of Arts in political science from the University of New Hampshire. She is a member of the New Hampshire Bar Association.
